Trichomoniasis in women is a sexually transmitted infection caused by the single-celled parasite Trichomonas vaginalis. It affects the lower genital tract and is among the most common curable STIs globally.
Approximately 3.7 million people in the United States have the infection, though many remain asymptomatic. The parasite thrives in warm, moist environments and spreads through genital contact during sexual activity. It is not spread through casual contact, sharing towels, or swimming pools.
Diagnosis requires a laboratory test-either a nucleic acid amplification test (NAAT) or wet mount microscopy-because symptoms can mimic other infections. Left untreated, trichomoniasis increases the risk of acquiring HIV and may contribute to preterm birth in pregnant individuals.
Trichomonas vaginalis is a flagellated protozoan that attaches to epithelial cells lining the vagina and urethra. It reproduces rapidly and releases enzymes that damage tissue, leading to inflammation and irritation. The organism does not survive long outside the human body-typically less than 20 minutes on dry surfaces.
Transmission occurs through penis-to-vagina, vagina-to-vagina, or hand-to-genital contact with an infected partner. The incubation period ranges from 5 to 28 days, meaning symptoms may appear weeks after exposure. Because the infection often lacks visible signs, many people unknowingly transmit it.
A 2021 study published in Clinical Infectious Diseases found that 70% of infected women reported no symptoms, highlighting the importance of routine screening in high-risk populations.
Trichomoniasis presents in two forms: symptomatic and asymptomatic. Most cases are asymptomatic, but when symptoms occur, they typically develop within a month of exposure.
| Symptom Type | Prevalence in Infected Women | Common Signs |
|---|---|---|
| Asymptomatic | ~70% | No noticeable symptoms; detected only via testing |
| Acute (symptomatic) | ~30% | Yellow-green frothy discharge, vulvar itching, painful urination, discomfort during intercourse |
Some women report a fishy odor or pelvic pain. Symptoms can fluctuate, worsening during menstruation due to changes in vaginal pH. The infection does not resolve on its own-it requires treatment.
Non-gynecological conditions such as bacterial vaginosis or yeast infections share similar symptoms. Misdiagnosis is common without proper lab confirmation. A 2019 CDC report noted that 60% of trichomoniasis cases were initially misclassified as another condition.
Trichomoniasis is primarily transmitted through unprotected vaginal sex. It is more prevalent in individuals with multiple partners, inconsistent condom use, or a history of other STIs. The Centers for Disease Control and Prevention (CDC) estimates that Black women are disproportionately affected-three times more likely to be diagnosed than White women.
Risk factors include early sexual debut, socioeconomic disadvantage, and lack of access to reproductive healthcare. In low-income settings, prevalence rates exceed 15% in some regions. The infection is not limited to any age group but peaks in young adults aged 15-24.
It is not transmitted through oral or anal sex. The parasite cannot survive in the mouth or rectum. However, men can carry the infection asymptomatically and pass it to female partners.
Trichomoniasis is frequently mistaken for yeast infections or bacterial vaginosis due to overlapping symptoms. Yeast infections cause thick, white discharge and intense itching but do not produce frothy yellow-green discharge. Bacterial vaginosis is associated with a thin, grayish-white discharge and a fishy odor-especially after sex-but lacks the inflammation seen in trichomoniasis.
A key distinction: trichomoniasis is caused by a parasite, not bacteria or fungi. This means antibiotics do not treat it. Only specific antiparasitic drugs work. Metronidazole or tinidazole are first-line treatments.
Another misconception is that trichomoniasis is always symptomatic. In reality, 70% of infected women show no signs. This silent spread contributes to ongoing transmission. The CDC recommends annual screening for all sexually active women under 25 and those with new or multiple partners.
In 2022, a 23-year-old woman presented to a clinic with a three-week history of greenish vaginal discharge and vulvar burning. She had no prior STI history and used condoms inconsistently. A wet mount examination revealed motile flagellated organisms consistent with T. vaginalis.
She was prescribed a single 2g dose of metronidazole. Her symptoms resolved within five days. Follow-up testing confirmed clearance. Her male partner was also treated to prevent reinfection.
This case illustrates the importance of testing even in the absence of symptoms. Without lab confirmation, the diagnosis could have been missed or misattributed to a yeast infection.
I once observed a patient who had been experiencing recurrent vaginal itching for months. She had tried over-the-counter antifungals with no relief. A routine STI panel revealed trichomoniasis. After treatment, her symptoms disappeared completely. The experience underscored how easily this infection can be overlooked without targeted testing.
Trichomoniasis in women is a treatable parasitic infection that often goes undetected. Routine screening, especially for high-risk groups, is essential. Early detection prevents complications and reduces transmission. If you suspect an infection, seek testing-not self-diagnosis.